Here are the 10-K annual reports from Polaryx Therapeutics, Inc. (PLYX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PLYX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLYX filings page.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing disease-modifying therapies for rare pediatric lysosomal storage disorders, including neuronal ceroid lipofuscinoses (CLN2 and CLN3), Krabbe disease, Tay-Sachs and Sandhoff diseases, and Niemann-Pick disease types A and B.
The lead candidate PLX-200, an oral gemfibrozil-based formulation, has extensive preclinical data across multiple animal models, three FDA orphan drug designations and Fast Track status in select NCL indications, with a Phase 2 SOTERIA basket trial in four LSDs expected to start in the second half of 2026.
Additional programs include small molecules PLX-300 and PLX-100 and gene therapy PLX-400, all licensed primarily from Rush University Medical Center, supported by a services agreement with controlling stockholder Mstone. As of February 1, 2026, Polaryx had 47,343,297 common shares outstanding.